Glutathione Metabolism in Adolescents With Type 1 Diabetes - Study A

Diabetes Mellitus, Type 1 Clinical Trial

Official title:

Regulation of Glutathione Homeostasis in Adolescents With Type 1 Diabetes - Study A

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00858897
• Other study ID #: JDRF 1-2006-627-A
• Status: Completed
• Phase: N/A
• Start date: June 2007
• Est. completion date: February 2009

Study information

• Verified date: June 2023
• Source: Nemours Children's Clinic
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Glutathione is normally present at high (millimolar) levels in blood and plays an important role in the body's defense against oxidative stress, that is, against the damage caused to the body by reactive oxygen species produced by the metabolism of most nutrients, including glucose. Glutathione is a small peptide made from 3 amino acids, glutamate, cysteine, and glycine.

This study is looking at how blood sugar levels may affect the way glutathione is made and used by the body. Since glutathione is continuously synthesized and broken down, the amount of glutathione present in blood depends on the balance between its rate of synthesis and its rate of use.

In earlier studies, the investigators found that in poorly controlled diabetic teenagers, glutathione was low, not because its production was decreased, but because it was used at an excessive rate. In this study, the investigators want to determine how short-term changes in blood sugar levels affect glutathione levels. This will help improve our understanding of how diabetes affects metabolism.

Description:

Adolescents with uncomplicated T1D will receive two, 5-hour infusions of deuterium-labeled cysteine on 2 separate days, a few weeks apart, while blood glucose will be maintained, using intravenous insulin infusion:

• in the hyper-glycemic range (200-250 mg/dL) on one study day, and

• near normoglycemia (80-140 mg/dL) on the other study day.

The order of the study days will be randomized.

We will determine whether the level of blood glucose at the time of study affects blood glutathione concentration, and, if so, whether this is associated with changes in the fractional rate of glutathione synthesis, as determined from the incorporation of labeled cysteine into blood glutathione over the course of the 5-hr infusion of labeled cysteine.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: February 2009
• Est. primary completion date: February 2008
• Accepts healthy volunteers: No
• Gender: All
• Age group: 14 Years to 18 Years

Eligibility

Inclusion Criteria:

• Type 1 diabetes, using usual criteria such as: glycosuria, hyperglycemia prior to treatment

• BMI <25 kg/m2

• Age 14-18

• HbA1c>7.5%

• No evidence of diabetic complications

• Written informed consent from parents or legal guardian, and assent from patient

Exclusion Criteria:

• Presence of significant anemia (hemoglobin <11g/dL)

• Presence of intercurrent illness such as infection

• Presence of chronic disease such as other endocrine deficiency, chronic respiratory or cardiac disease

• Chronic use of medication other than insulin

• Use of vitamin or mineral supplements within 2 weeks of study

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 1

Intervention

Other:
• Cysteine isotope infusion at normoglycemia vs hyperglycemia
L-[3,3-2H2]cysteine

Drug:
• Regular Insulin
Regular insulin, IV, as needed to maintain blood glucose in near-normoglycemic range (80-140 mg/dL) or hyperglycemic range (200-250 mg/mL) during metabolic studies

Locations

Country	Name	City	State
United States	Nemours Children's Clinic	Jacksonville	Florida

Sponsors (2)

Lead Sponsor	Collaborator
Nemours Children's Clinic	Juvenile Diabetes Research Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Glutathione Concentration	umol/L	Up to 30 minutes post- 5 hour infusion on Day 1 (First Intervention) and up to 30 minutes post- 5 hour infusion on Day 14 (Second Intervention)